In the study, patients with early-stage inherited breast cancer were treated with chemotherapy followed by the targeted drug Olaparib before operating, and all survived the critical three-year period post-surgery.


As larger-scale trials are planned, this discovery could become the most effective treatment to date for patients with early-stage breast cancer linked to inherited BRCA1 and BRCA2 gene mutations.